ArticleCancer immunology, immunotherapy : CII2024

Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.

Ziyang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.